Contribute Try STAT+ Today

The drug maker Biogen announced late Thursday that it would license two preclinical drugs from Sangamo Therapeutics, both of which use a genome-editing technology called zinc fingers to regulate the expression of genes involved with neurological diseases like Alzheimer’s and Parkinson’s.

For Biogen, the large partnership deal represents a big bet both scientifically and financially that genome editing holds the key to treating diseases that have eluded the best efforts of drugmakers to find effective medicines. For Sangamo, the deal helps to validate the potential of zinc fingers as a genome editing technology at a time when it’s been eclipsed in many ways by CRISPR.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • As a Parkinson’s sufferer, gene therapy is a the only way to help us battle these nuerological disorders
    Sign me up to be in the trial
    I’d risk my life for the cause

Comments are closed.